ISRCTN19339824CompletedNot Applicable
Effects of Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) on insulin secretion and energy balance in human obesity and diabetes
Record Provided by the NHSTCT Register - 2006 Update - Department of Health0 sites6 target enrollmentStarted: September 29, 2006Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 6
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- Male
Inclusion Criteria
- •Obese male subjects between age 20-60 years will be recruited by advertisement and by invitation of eligible patients who have already undergone glucose tolerance testing. This is a pilot study and will involve the following groups. 6 lean (BMI 20-25 kg/m2) subjects with normal glucose tolerance and 6 obese (BMI >30 kg/m2) type-2 diabetic patients on treatment with diet alone. Eligible subjects will be asked to provide informed written consent, and studies will be undertaken in accordance with the Declaration of Helsinki.
Exclusion Criteria
- •Any co-morbid conditions requiring drug therapy that cannot be discontinued, any regular drug treatment that cannot be discontinued, any diseases of the heart, lungs, liver, gut or endocrine glands, alcoholism, eating disorder, and for the diabetic group - poorly controlled diabetes (defined as HbAlc >8.0% for the purposes of this study)
Investigators
Similar Trials
Active, not recruiting
Phase 1
GLP-1 and persons without stroke.EUCTR2016-001221-14-DKHerlev Gentofte Hospital
Active, not recruiting
Phase 1
GLP-1 and strokeMedDRA version: 19.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersStrokeEUCTR2016-001219-18-DKHerlev Gentofte Hospital30
Completed
Phase 2
Effects of Glucagon-Like Peptide-1 (GLP-1) administration on gastric emptying during periods of hyperglycaemia in healthy volunteers.Glycaemic control and gastric emptyingMetabolic and Endocrine - Other metabolic disordersACTRN12613001384741Dr Mark Plummer15
Completed
Phase 2
Does exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in critically ill patients with pre-existing type-2 diabetes?Blood GlucoseType-2 DiabetesMetabolic and Endocrine - DiabetesACTRN12610000185066Adam Deane10
Completed
Phase 2
Exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in the critically ill.Blood GlucoseMetabolic and Endocrine - Other metabolic disordersACTRN12609000093280Adam Deane8